To identify regions of aberrant DNA methylation in acute lymphoblastic leukemia (ALL) cells of different subtypes on a genome-wide scale. Materials & methods: Wholegenome bisulfite sequencing (WGBS) was used to determine the DNA methylation levels in cells from four pediatric ALL patients of different subtypes. The findings were confirmed by 450k DNA methylation arrays in a large patient set. Results: Compared with mature B or T cells WGBS detected on average 82,000 differentially methylated regions per patient. Differentially methylated regions are enriched to CpG poor regions, active enhancers and transcriptional start sites. We also identified approximately 8000 CpG islands with variable intermediate DNA methylation that seems to occur as a result of stochastic de novo methylation. Conclusion: WGBS provides an unbiased view and novel insights into the DNA methylome of ALL cells.
Background DNA methylation at CpG dinucleotides is fundamentally important for cellular lineage commitment and memory [1] . Aberrant DNA methylation patterns are frequently observed in cancers, although the underlying mecha nisms and the functional consequences of cancer related DNA methylation changes have remained elusive. The recent discov ery of recurrent somatic mutations in key enzymes involved in the regulation of DNA methylation in hematologic malignancies suggests that disruption of the DNA methyl ation pattern can drive the transformation of normal cells to malignant states [2] [3] [4] .
Acute lymphoblastic leukemia (ALL) comprises a genetically heterogeneous group of leukemias that originates from the trans formation of common lymphoid progenitor cells into malignant cells, characterized by excessive proliferation of undifferentiated cells [5] . The precise molecular mechanisms that are involved in the transformation of lymphoid progenitor cells into ALL cells are currently unknown. Epigenetic changes may play an important role in the leukemic trans formation in combination with somatically acquired mutations or other genetic aberra tions. Using arraybased DNA methyl ation analysis we and others have previously shown that DNA methylation patterns of ALL cells discriminate between cytogenetic subtypes of ALL and that the vast majority of the dif ferential DNA methylation is enriched to CpG islands [6, 7] . Furthermore, DNA meth ylation marks in ALL have also been associ ated with relapse [8] , poor prognostics [9] and survival [10] . Historically, the focus of DNA methylation studies in cancer has been on CpG islands in gene promoter regions [11, 12] . More recently, unbiased wholegenome bisul fite sequencing (WGBS) of normal tissues and cancer cells has highlighted the impor tance of distal regulatory enhancer elements Research Article Wahlberg, Lundmark, Nordlund et al. as regions of dynamic DNA methylation and functional relevance for cell specification and maturation [13] [14] [15] . Enhancer regions can be identified using patterns of DNA methylation as low levels of DNA methylation often coincide with transcription factor (TF) binding sites [16] . A WGBS study in pediatric medulloblastoma recently identified specific unmethyl ated genomic regions that distinguish between subtypes and are enriched for subtypespecific TF motifs [17] .
In the current study we characterized the DNA methylomes of three pediatric Bcell precursor ALL (BCPALL) patients of different cytogenetic subtypes and one pediatric TALL patient using WGBS. In addition, we sequenced the transcriptomes of the ALL patients to assess the interplay between DNA methyl ation and gene expression. The results shed light on the DNA methylation patterns in ALL cells at diag nosis, and identify differential methylation in ALL cells compared with normal B and T cells.
Material & methods

Ethics statement
The study was approved by the regional ethical review board in Uppsala, Sweden and the guardians of the pediatric ALL patients and the healthy subjects provided informed consent.
Patients
Swedish ALL patients (P1P4) included in this study were diagnosed and treated according to the Nor dic Society for Pediatric Hematology and Oncology (NOPHO) ALL2000 protocol [18] . The ALL patients (P1P4) were carefully selected to be typical repre sentatives of four major subgroups of childhood ALL based on unequivocal results from cytogenetic analy ses. We reasoned that these four large cytogenetically defined subgroups of ALL should allow identification of DNA methylation patterns that are shared between ALL subtypes and patterns that are subgroupspecific. BCPALL with the t(12;21) ETV6-RUNX1 gene fusion (P1) is the largest homogeneous cytogenetically defined subgroup of BCPALL representing 20-25% of the patients with pediatric ALL. The patients with nonrecurrent (P3) or undetectable (P2) largescale cytogenetic aberrations constitute two large subgroups of BCPALL. TALL (P4) represents 10% of the pediat ric ALL cases. The patients P1P4 have previously been wholegenome sequenced and are denoted: ALL458 (P1), ALL501 (P2), ALL707 (P3) and ALL559 (P4) in this study [19] .
To compensate for the small size of our WGBS 'discovery cohort' with four ALL samples, we used data from a large cohort of approximately 700 ALL Nordic patients (and control cells) analyzed by 450k
Bead Arrays (Illumina) [6] to validate some of the observations made by WGBS.
For validation and control of differentially meth ylated regions (DMRs) discovered in the BCPALL patient (P1) with the t(12;21) ETV6-RUNX1 sub type three samples (ALL_C1, ALL_C2 and ALL_C3) with the same ALL subtype from a Canadian cohort (SainteJustine Hospital, Montreal, Canada) were included in our study [20] .
Sample preparation & DNA extraction
Mononuclear cells from the ALL patients (P1-P4) were collected from bone marrow aspirates by Ficoll Isopaque (Pharmacia) densitygradient centrifugation at the time of diagnosis. The leukemic cell content of the samples exceeded 90% of the total cell con tent. DNA and total RNA were extracted from the ALL patient samples using reagents from the AllPrep DNA/RNA Mini Kit (QIAGEN). CD3 + T cells and CD19 + B cells were isolated from peripheral blood from healthy Swedish blood donors by positive selec tion using CD19 + and CD3 + Microbeads and MACS cell separation reagents (Miltenyi). DNA and total RNA was extracted from the cells by the AllPrep DNA/RNA Mini Kit (QIAGEN). RNA concentra tions were determined using Qubit (ThermoFisher) and the integrity of the RNA was verified by Agilent Bioanalyzer 2100 (Agilent technologies).
Whole-genome bisulfite library preparation & sequencing
Wholegenome bisulfite sequencing libraries were pre pared using the Illumina TruSeq DNA Library pre paration kit. A total of 4 μg of sample DNA together with 20 ng of unmethylated lambda DNA (Promega) were fragmented by acoustic sonication (Covaris). Three parallel libraries were prepared from each sample starting with 1 μg of DNA. Endrepair, Atailing and ligation of adaptors were performed according to the Illumina TruSeq protocol. Subsequent bisulfite conver sion of the sequencing libraries was performed using reagents from the EpiTect Bisulfite kit (Qiagen). Bisul fite converted adaptorligated fragments were amplified by PCR in a reaction mixture containing 15-20 μl of DNA template, 5 μl Pfu Turbo Cx Reaction buffer (Stratagen), 5 μl Illumina primer cocktail mix, 1.25 μl dNTP mix (10 mM), 2.5 units Pfu TurboCx Hotstart DNA polymerase (Stratagen) and H 2 O to a final vol ume of 50 μl. Cycling conditions during PCR were 5 min at 95°C and 30 s at 98°C, followed by six cycles of 10 s at 98°C, 30 s at 65°C, 30 s 72°C, followed by 72°C for 5 min. The bisulfiteconverted sequencing libraries were subjected to pairedend 100 bp sequencing on a HiSeq 2000 sequencing system (Illumina).
future science group Stochastic de novo DNA CpG island methylation in acute lymphoblastic leukemia cells Research Article Alignment of bisulfite-converted sequence reads to reference genome Pairedend bisulfite converted reads from ALL patients and controls were mapped to the human reference genome (hg19) according to methods described by Johnson et al. [21] . Prior to aligning the sequence reads to the reference genome, adaptor sequences and bases with a low quality score (<20) were removed using CutAdapt [22] . The reads were aligned to in silico bisul fite converted genomes using the Burrows-Wheeler aligner (BWA) [23] . Picard [24] was used to remove duplicated reads. In addition read pairs were removed if they did not map at the expected distance based on the average library insert size. Reads with a low map ping quality score (<20) were also removed. Second, read pairs were removed if they mapped in the wrong orientation. Third, reads that mapped to both the forward and reverse converted reference strands were removed. Finally, reads were discarded if the mismatch rate to the converted reference exceeded 2% over an alignment length.
DNA methylation calling
The first and last three bases of each readpair were removed to avoid biased methylation calls during the first and last three sequencing cycles due to introduc tion of unmethylated cytosines during endrepair. The BisSNP package (version 0.78) was used to deter mine the DNA methylation levels genomewide [25] . To improve the precision of the methylation calls, the local realignment and base recalibration functions of BisSNP was applied. Raw calls were subsequently filtered using the BisSNP VCFpostprocess walker. Methylation values from the forward and reverse strands of individual CpG sites were combined into a single value and used in all downstream analysis. CpG sites that BisSNP called as heterozygous and CpG sites located on sexchromosomes were removed from all downstream analysis. Low coverage bisulfite sequenc ing data from eight Bcell and 18 Tcell samples were combined into cell typespecific pools and methylation levels were calculated in the pools. The DNA methy lome data (WGBS) from hematopoietic stem/progeni tor cells (CD34 + CD38 Lin ) were downloaded from GEO (accession no. GSM791828 [26] ).
Average DNA methylation levels were calculated in 1kb windows genomewide for ALL P1-4, pooled B and T cells and of B and T cells from individuals with low coverage sequencing data that constitute the pooled B and Tcell controls. To examine the effect of sequence read coverage on DNA methylation lev els calculated in 1kb windows, the aligned reads from patient P4 was downsampled using Picards Down sampleSam to sequence coverages ranging from 3× to 25×, followed by recalling the DNA methylation levels using BisSNP.
Statistical analysis of data & visualization
The statistical analyses and visualization of the data were performed using the R framework (version 3.2.2).
Smoothing of DNA methylation data & identification of differentially methylated regions
The Rpackage bsseq [27] was used to smoothen methyl ation calls from WGBS data, segment data and call DMRs between sample pairs. To call a segment as a DMR a minimum of three consecutive CpG sites and an average difference >0.3 in the DNA methyl ation levels between an ALL sample and the control were required. BCP ALL samples (P1-P3) were com pared with a pool of B cells (see above) and the TALL sample (P4) was compared with a pool of T cells.
To asses normal variation in B and T cells, eight individual Bcell samples and eight individual Tcell samples were compared with the remaining pooled Bcell and Tcell samples respectively, calling DMRs as described above. DMRs with an average mapability score (wgEncodeCrgMapabilityAlign100mer, down load from UCSC table browser) of <0.5 across seg ments and DMRs where the average coverage in any of the compared pair of samples was less than three or larger than 50 (except in pooled samples), were removed to ensure that potential mapping errors did not inflate DMR detection.
Methylation levels of DMRs in ALL samples were considered to be shared with control cells if the average DMR methylation level of the other control cell was closer to the ALL sample than the control cell in the compared pair. When comparing methylation levels of DMRs between ALL cells, an average methylation dif ference of <0.3 for the DMRs was considered as simi lar. The degree of base overlap (defined by the Jaccard similarity index) between DMRs detected in ALL cells and control cells were computed using BEDTools [28] .
Principal component analysis
Principal components of DNA methylation data from CpG sites in CpG island shores (defined as 2 kb on either side of a CpG island) were determined using the function prcomp in R.
Genomic annotation & enrichment analysis of DMRs
RefSeq and CpG island annotations were downloaded using the UCSC table browser (GRCh37/hg19, track  RefSeq Genes, table refGene and RefSeq CpG Islands,  table cpgIslandExt TSS1500 and intergenic regions. CpG island shores were defined as 2 kb of sequence flanking a CpG island. Each base in the DMRs was assigned to a genomic fea ture, and the number of bases in the individual features was divided with the total number of bases defined as a DMR. Sample specific genomic backgrounds were derived by intervals of CpG sites with sufficient read coverage no more than 2 kb apart. The genomic back ground provides a set of intervals where DMRs can theoretically be called and the genomic background was used to compute an enrichment score for each genomic feature.
Evolutionary conservation in DMRs
PhyloP basewise score derived from alignment of 46 vertebrate species were downloaded (UCSC table browser) and used to infer evolutionary conservation in DMR sequences. The PhyloP score profiles along DMRs were calculated by binning the genomic range of each DMR with flanks of the same length as the DMR into 50 equal sized genomic ranges. The aver age PhyloP score of each bin was calculated and then averaged per bin across all DMRs in each sample. As a general control of conservation we used a size matched set of fragments randomly chosen from regions in the genome where the CpG sites are positioned sufficiently close to each other to be called as a DMR using the DMR detection settings described above.
Functional annotations & enrichment of DMR to chromatin states
Chromatin state maps generated by the Roadmap Epigenomics project [29] were used to ascertain genomic positions and infer functions of DMRs. An 18state chromatin map constructed from the six histone marks (H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3 and H3K27ac) was downloaded [30] for B cells (Epigenome ID: E032), T cells (Epigenome ID: E034) and CD34 + cells (Epigenome ID: E050). Fold enrichment of DMRs to each state was calculated by computing the proportion of bases overlapping with each chromatin state, followed by division by the genomewide proportions of bases in different chroma tin states. Significance thresholds for enrichment were set by empirical pvalues determined by permutation testing. DMRs were randomly shuffled 1000times within the theoretical genomic intervals described earlier using BEDTools [28] .
TF binding & motif enrichment analysis
Chromatin immunoprecipitation sequencing data from the ENCODE project [31] was used to obtain infor mation about TF binding sites for 161 TFs. Enrich ment of TF binding motifs to DMRs was calculated as described by Kheradpour and Kellis [32] and imple mented in the program ENCODEmotifs [33] . Hierar chical clustering of a motif similarity matrix (down loaded from [34] ) was performed in order to describe the relationship between TF binding sites motifs and used to order TFs into groups.
Gene-expression analysis
Ribosomal RNA was depleted from 1 μg total RNA using RiboZero (Illumina) and strandspecific RNA sequencing libraries were constructed with the Script Seq V2 Kit (Epicentre). Libraries were sequenced with either 100 or 50 bp sequencing chemistry (pairedend) on a HiSeq2000/2500 sequencing instrument (Illu mina). Reads were mapped to the reference genome (human_g1k_v37) using Tophat2 (version 2.0.4) with default settings [35] . The number of fragments per tran script was calculated from Tophat bam files using the function featureCounts in Rsubread Rpackage [36] and fragments per transcript per kilobase per million was computed by the function rpkm in the package edgeR [37] . When used in differential expression ana lysis between ALL cells and B and T cells, transcript fragment counts were normalized to log 2 counts using the voom function in the limma Rpackage [38] . A lin ear model was fitted to the data to calculate differences in expression level and pvalues corrected for multiple testing were determined using the eBayes function in limma. We considered a transcript as differentially expressed between samples if the log 2 foldchange was >1 and pvalue <0.01. DMRs were assigned to a pro teincoding transcript (RefSeq) if a DMR was located within 10 kb upstream of a transcription start site to 5 kb downstream of a proteincoding transcript.
Gene ontology term analysis of CpG islands
We used Genomic Regions Enrichment of Annota tions Tool (GREAT) [39] to investigate enrichment of biological processes and phenotypic associations to CpG islands.
Analysis of heterogeneity of CpG island methylation in ALL cells
DNA methylation patterns within individual sequence reads were used to examine CpG islands with inter mediate DNA methylation levels. Readpairs with less than five CpG sites and lower than an average 5× cov erage across a CpG island were excluded from the anal ysis. The readpairs were categorized into concordantly methylated (either unmethylated or methylated) if 90% of the CpG sites along a readpair showed the same methylation state or as discordantly methylated if a readpair contained at least 10% of either methylated or unmethylated CpG sites. [6] ranged between 0.97 and 0.98 (r) per patient (Supplementary Figure 1A & B) . In the WGBS data from the four ALL samples we did not find evidence of DNA methylation at other sites than CpG dinucleotides. The genomewide DNA methyl ation levels for individual CpG sites are largely bimod ally distributed, with the majority of CpG sites either unmethylated or completely methylated in the ALL samples (Supplementary Figure 2) . Using a method described by Burger et al. [16] to identify segments of continuous hypomethylation, we did not find evidence of large megabasescale partially methylated domains in the ALL patients like those observed in colon cancer [40] and medulloblastoma cells [17] .
We first explored the global DNA methyla tion patterns by determination of the median DNA methyl ation levels in 1 kb windows across the four ALL genomes and genomes of pooled B cells (n = 8) and T cells (n = 17) from healthy blood donors. We observed an average approximately 5% increase in global DNA methylation levels in ALL cells compared with B and T cells (p < 2.2 × 10 16 ) ( Figure 1A ). We also observed individual variation in genomewide median CpG methylation levels between the ALL patients and between the lowcoverage B and T cells from the individual donors. To verify that the results from low coverage B and T cells are comparable with the data from ALL P1-4 we downsampled data from the TALL (P4) patient to 3× sequence coverage. We observed marginal differences in median DNA methylation lev els in 1 kb windows across the genome in the range from 25× to 3× coverage (Supplementary Figure 3) . The individual variation in genomewide CpG methylation levels is supported by 450k BeadArray data from a large number of ALL patients (n = 550) [6] with different 1.0 P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P 3 P 4 B c e l l T c e l l P 1 P 2 P [41] to examine the relationship between 18 reoccurring combinations (states) [42] of histone modifications and levels of DNA methylation in the ALL cells ( Figure 1C) . Expectedly, CpG sites over lapping with states annotated as active transcription start sites (TSS) show the lowest levels of DNA meth ylation, whereas CpG sites that map to 'gene bodies' in actively transcribed genes have the highest DNA methylation levels. This analysis also shows that the CpG sites located to active enhancer and Polycomb repressed chromatin states show large variability in DNA methylation levels in the ALL cells.
Differential DNA methylation in low-density CpG regions in ALL cells
To comprehensively define DMRs between ALL cells and nonleukemic cells, we compared the individual BCPALL patients (P1-P3) to pooled B cells and the TALL patient (P4) to pooled T cells. For calling a genomic region as a DMR, we required a minimum of three CpG sites per DMR, more than 3× sequenc ing coverage for each CpG site, and an average abso lute difference >0.3 in the DNA methylation levels between an ALL sample and the control pool. Using these stringent criteria for calling DMRs, we identi fied between 74,267 and 103,275 DMRs in the three BCPALL patients (P1-P3) and 69,849 DMRs in the TALL patient (P4) ( Table 2 & Supplementary Table 2 [GSE76270]). The contribution by normal variation between the B and Tcell samples in the pooled B and T controls to the number of DMRs detected in the ALL samples was estimated to be between 4529 and 27,603 DMRs for B cells and between 2184 and 7947 DMRS for the T cells. Thus the contribution by normal variation to the number of DMRs detected in the ALL cells appears to be minor. Due to the fact that the data from the B and T cells have low sequence coverage, the accuracy of the analysis is lower than for the ALL samples with high coverage. The BCP ALL patients P2 and P3 have an excess of hypometh ylated DMRs, with a ratio of hyper to hypometh ylated DMRs of 0.78 and 0.64, respectively, whereas the BCPALL patient P1 shows a balanced number of hyper to hypomethylated DMRs. On the con trary, the TALL sample P4 shows a large excess of hypermethylated DMRs (ratio 2.7) ( Table 2) .
We validated the DNA methylation levels in DMRs by comparing the methylation levels determined by WGBS within each DMR against βvalues obtained from 450k BeadArrays. Only approximately 20% of the DMRs identified by WGBS are supported by at least one probe on the 450k BeadArray. For these DMRs we observe correlation values (r) between 0.87 and 0.93 (Supplementary Figure 4A) . The remain ing approximately 80% of the DMRs are not cov ered by any probe on the 450k BeadArray and only 0.2-1.6% of DMRs are covered by more than five probes (Supplementary Figure 4B) . The limited over lap between DMRs identified by WGBS and 450k BeadArrays highlights the advantage of WGBS to discover DMRs across the genome.
The DMRs cover on average 31 Mb per ALL genome (range: 24-42 Mb), which corresponds to approximately 1% of the genome. The number of CpG sites located within the DMRs in each patient varies between 536,237 and 1,011,619 (Table 2 ). The median number of CpG sites per DMR across all comparisons ranges between 5 and 6, which implies that the DMRs are predominantly located in regions with a lowdensity of CpG sites. The majority of the DMRs in the ALL samples (74-81%) are less than 500 bp in size, and only a small minority of them (0.4-1.4%) are larger than 2 kb (Figure 2A) Figure 3A) . Of the ALLspecific DMRs that are not present in control cells, between 63 and 83% are shared between the ALL cells ( Figure 3B) .
In lowcoverage WGBS data from three addi tional patients with the t(12;21) ETV6-RUNX1 BCPALL subtype represented by patient P1 in our study we observe a similar number of DMRs (range: 62,210-56,327) that overlap (Jaccard similarity index 0.23-0.34) with the DMRs in BCPALL patient P1 (Supplementary Figure 5A) . Not surprisingly the correlation in genomewide DNA methylation lev els between the four t(12;21) ETV6-RUNX1 sam ples subjected to WGBS is lower than that between 163 t(12;21) ETV6-RUNX1 samples analyzed by the 450k BeadArrays [6] that targets a 60fold lower num ber of CpG sites in selected CpGrich genomic regions. Principal component analysis of DNA methylation lev els at CpG sites located in CpG island regions shows a strong subtype specific clustering of the ALL samples P1 and C1-3 (Supplementary Figure 5B) . Figure 4A shows an example of a large DMR region that harbors two adjacent hypomethylated DMRs that were iden tified in each of the four BCP t(12;21) patients. The DMR region spans 19 kb and maps to the TERF2 (also known as TRF2). TERF2 is involved in the regulation of telomere length, and overexpression of TERF2 in cancer cells prevents the elimination of the cancer cells by natural killer cells [43] . Notably, the large DMR that spans the TERF2 gene contains only one probe on the 450k BeadArray, which explains why this large DMR has not previously been observed. According to RNAsequencing data from ALL patients (n = 125) of different ALL subtypes, the TERF2 locus shows elevated expression in a large proportion of BCPALL t(12;21) patients compared with ALL patients with other subtypes and control B and T cells (Wilcoxon; p = 4.79 × 10 7 ; Figure 4B ). The subtypespecific func tional role of the TERF2 locus in t(12;21) BCPALL warrants further studies of telomere function in this subtype.
Enrichment of hematological TF binding sites to DMRs in ALL cells
We annotated the DMRs to gene and CpG island regions and tested for an enrichment of DMRs to these genomic regions ( Figure 5A ). The DMRs are under represented in intergenic regions and enriched to gene Figure 6) . To increase the resolution of the annotation of DMRs, we used chromatin state maps from normal B, T cells and CD34 + cells ( Figure 5B ) [41] . The DMRs in ALL cells are enriched to regions predicted to be enhancer elements or TSS, whereas DMRs are underrepresented in regions marked as actively transcribed, contain ing repeats, silenced and as heterochromatin. As has been observed previously in ALL [6] , hypermethylated DMRs in ALL samples are overrepresented in biva lently marked TSS and enhancer states and to regions repressed by polycomb proteins (ReprPC). Chromatin immunoprecipitation sequencing (ChIPSeq) data for 161 TFs from multiple cell types (ENCODE proj ect [44] ), show that a third (32-35%) of the DMRs in the ALL cells overlap with at least one annotated TF binding site. To identify TFs of potential impor tance for ALL we scanned the DMRs against a data base of approximately 2000 known and predicted TF binding motifs [32] . As expected, we observe an overrepresentation of blood cellspecific TF binding motifs in the DMRs in the ALL cells ( Figure 5C ). The enrichment of TF binding motifs to hypo and hyper methylated DMRs displays distinct patterns in ALL cells. Hypomethylated DMRs in BCPALL are, for example, enriched for PAX5 and ERG motifs, while hyper methylated DMRs in all of the samples show an overrepresentation of NFκB (NFκBlight chain enhancer of activated B cells) binding motifs. PAX5 plays an important role in Bcell differentiation [45] , and is somatically mutated in approximately 30% of pediatric BCPALL cases [46] , while NFκB plays a central role in Bcell activation [47] . Thus DMRs could serve as footprints to detect previously unknown TFs and pathways that are important for ALL development and progression.
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Features of DMRs associated with differentially expressed genes
Next we interrogated potential effects of DMRs on gene expression using RNAsequencing data from three of the ALL patients (P1, P2, and P4) and B and T cells, for comparison (ALL patient P3 is not included here due to lack of RNAsequencing data). Approxi mately 50% of the annotated protein coding genes are expressed (fragments per transcript per kilobase per million [FPKM] >1) in each ALL sample, and of them 880-1447 genes are differentially expressed between ALL cells and control B or T cells (defined as p < 0.01, 19 ) and a larger relative number of DMRs are associated with individual dif ferentially expressed genes (median: 0.053 vs 0.041; p = 9.1 × 10 81 ), than DMRs associated with genes that do not display differential expression between ALL cells and normal blood cells (Figure 6A-D) . 
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Heterogeneity of DNA methylation at CpG islands in ALL cells
As we observed an enrichment of DMRs to CpG islands in the ALL cells ( Figure 5A) Figure 8) . DNA methylation data from 450k BeadArrays from a larger number of ALL samples (n = 550) confirm this pattern of highly variable and increased DNA methylation levels at CpG sites within CpG islands in ALL samples ( Figure 8B ). According to gene ontology term analysis, inter mediately methylated CpG islands are enriched to genes that are expressed in early development and to homeobox genes (Supplementary Table 5 TCF7L2_known7  TCF7_2  TCF7L2_disc2  TCF7_1  TCF7L1_1  TCF7L2_known6  TCF7L2_known5  RUNX2_4  RUNX2_6  RUNX3_4  RUNX3_2  RUNX_1  RUNX1_9  RUNX2_2  PRRX1_4 AP1_known9  ARNT_2  CLOCK_1  MYC_known2  MYF6_2  NHLH1_5  NHLH1_3  TCF3_1  TCF12_disc1  LMO2_1  TCF3_6  ZEB1_known3  FIGLA_1  TCF3_2  SNAI2_1  TCF4_2  MESP1_1  TCF3_7 Figure 8C ). According to RNA sequence data, the majority (79%) of genes that are proximal to differentially methylated CpG islands with inter mediate methylation levels are not expressed in the ALL cells or in the control cells, which is in sharp contrast with genes near unmethylated CpG islands, where the majority (78%) of the genes are expressed ( Figure 8D; Supplementary Figure 9) .
To clarify the origin of intermediate DNA methyl ation at CpG islands in ALL patients, we examined the DNA methylation patterns along the individual sequence reads, each of which originates from an indi vidual ALL cell, using a concept similar to that pre sented by Landau et al. [48] and by Landan et al. [49] . As illustrated (Figure 9A ), intermediate DNA meth ylation levels can occur as a consequence of admixture of cells with different CpG site methylation patterns between individual sequence reads, but with concor dant methyl ation levels for CpG sites along each read. Alternatively, the intermediate methylation levels may arise from admixture of ALL cells with variable and discordant methylation states along the sequence reads. These two mechanisms can be distinguished with the aid of the individual DNA sequence reads that cor respond to individual DNA molecules that originate from a single cell, by calculating the proportion of discordantly methylated reads, in combination with the methylation variance between the DNA sequence reads across CpG islands (see 'Materials & methods' section).
According to the combined analysis of these two metrics, only a minority of the CpG islands have concordant methylation levels along the sequence reads in combination with a large variance in DNA methyl ation between the sequence reads. These rare DNA methylation patterns at CpG islands could be the results of concordant clonal methylation differ ences like allelespecific methylation, or they could represent imprinted genomic regions. Out of the total 8204 CpG islands with intermediate and variable DNA methylation levels we identified only 101 CpG islands with less than 50% discordant sequence reads and a variance between the sequence reads that was larger than 12.5% that are shared between at least two of the ALL samples (Supplementary Table 6 ). Gene ontology analysis of genes associated with such CpG islands revealed a 28fold enrichment (hyper geometric test; p = 8.9 × 10 10 ) to known imprinted loci Table 7 ).
The by far largest part of the variability in DNA methylation appears to be the result of admixture of ALL cells with discordant methylation states along the chromosomes ( Figure 9B ). As can be seen by the grey areas in Figure 9B more than 71% of the CpG islands have discordant methylation patterns in more than half of the sequence reads in the four ALL samples (P1-P4). Thus we conclude that the increased DNA methylation and large variability in CpG islands in ALL cells is a result of an apparent stochastic methyl ation process leading to discordant DNA methylation between ALL chromosomes.
Discussion
Our analysis of the DNA methylome in primary pedi atric ALL cells from patients with four different cyto genetic backgrounds suggests that the global DNA methylation pattern in ALL is similar to that in a typi cal mammalian cell [15] . DNA methylation does not generally occur in CpGrich promoter regions, whereas regions with high methylation levels are found in genes and intergenic regions that are frequently interrupted by short stretches of hypomethylated CpG sites in low density CpG regions, commonly overlapping known enhancer regions. Concurrent leukemiaspecific differ ential methylation between the ALL cells and control cells primarily resides in CpG islands. The majority of the DMRs discovered in our study are not directly associated with differentially expressed genes, although we observe an enrichment of DMRs to differentially expressed genes, compared with genes that do not show differential expression in our analysis. Across all comparisons we observed that DMRs that are colocalized with differentially expressed genes are on average larger and display larger absolute differences in methylation levels than DMRs that are not associated with differential expression. These findings could reflect active binding of TFs, whereas for DMRs associated with genes without differential expression, the DNA methy lation differ ences could gradually disappear due to lack of bind ing of a TF, which would result in a reduced DMR size and diminishing DNA methylation. The TERF2 gene which contains two adjacent large DMR that are associated with strong differential expression of TERF2 in t(12;21) ETV6-RUNX1 ALL exemplifies such a functional DMR. We also noted an increased number of DMRs per gene that are associated with differentially expressed genes, suggesting that mul tiple active enhancers are required to significantly influence gene expression.
In normal cells, promoter CpG islands are hypo methylated with limited variation between cell types, similarly to what we observe for B and T cells (Figure 7 ). Hypermethylation of promoter CpG islands in tumor suppressor genes has been frequently observed [50, 51] , and it has been postulated that hypermethylation would contribute to tumor progression by silencing tumor suppressor genes. This concept was challenged in a recent study [52] , which showed that in seven can cer types, genes associated with hypermethylated CpG islands are already silenced in the corresponding nor mal cells, making it unlikely that hyper methylation per se would induce gene silencing and drive tumor progression. In the current study we found between 2000 and 4000 CpG islands with increased DNA methylation in ALL cells, which is in contrast with the low number (n = ∼350) of differentially methylated CpG islands that we detected compared with normal B and T cells. It is an interesting question how the pattern of inter mediately methylated CpG islands arises on the molec ular level. Bisulfite sequencing has the advantage that each sequence read is derived from a single chromo some, which allows investigation and quantification of intratumor DNA methylation patterns [49] . In our analysis, we observed that the bulk of the intermedi ately methylated CpG islands arise as a consequence of intrachromosomal variability of DNA methyl ation. Previously published results from a comprehen sive study in chronic lymphocytic leukemia (CLL) patients [48] used reduced representation bisulfite sequencing to assess the intrachromosomal structure of DNA methylation by analyzing the methylation states at four consecutive CpG sites. In concordance with our results, the bulk of the heterogeneity of DNA methylation in CLL originates from an apparently sto chastic process generating variability within chromo somes. The CLL study and a similar study of diffuse large B cell lymphoma tumors showed that despite the stochastic nature by which the methylation pattern arises, the increased intratumor heterogeneity in pro moter regions is associated with adverse clinical out come [53] . This finding suggests that enhanced epigen etic diversity could act as fuel for Darwinian selection, analogous to selection on genetic diversity that could promote malignant tumor development and resistance to treatment. Further research on intratumor hetero geneity of DNA methyl ation is warranted to fully com prehend the functional consequences and implications for treatment.
Conclusion
To date, the majority of DNA methylation stud ies have relied on data from arraybased and targeted DNA methylation assays. We used unbiased WGBS to acquire near complete genomewide information of DNA methylation patterns in ALL cells. We detected a large set of DMRs in ALL cells that are enriched to functional genomic regions, such as TF binding sites and hence could be important for ALL development and progression. The majority of DMRs that we iden tified are most likely not de novo acquired leukemia specific changes, but represents DNA methylation marks from previous cell developmental stages. Impor tantly, DNA methylation information can be valuable to determine the origin of the ALL cell. Our results also highlight that there is extensively increased DNA methylation in CpG islands and that intermediate and highly variable DNA methylation levels appear to arise as a consequence of intrachromosomal variability and not by concordant clonal methylation.
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Executive summary
• We employed whole-genome bisulfite sequencing to generate complete high-resolution maps of the DNA methylomes of primary cells from patients with pediatric acute lymphoblastic leukemia (ALL).
• Compared with normal human B and T cells, whole-genome bisulfite sequencing identified thousands of differentially methylated regions (DMRs) in the ALL cells from four patients of different cytogenetic subtype. The DMRs are aggregated to regions of low CpG density and are enriched to gene regions and functional genomic elements, such as enhancers and known leukocyte-specific transcription factor binding sites.
• According to RNA-sequencing the DMRs in the ALL cells that are associated with differentially expressed genes have an increased size, a larger difference in absolute methylation levels and an increased number of DMRs than DMRs that do not overlap with differentially expressed genes.
• Hyper-methylated DMRs are enriched to CpG islands and genes located nearby these CpG islands are usually not expressed in ALL nor in control B and T cells. This finding indicates that hyper-methylation of CpG islands is unlikely to play a functional role in promoting cancer development by turning off the expression of tumor suppressor genes, contrary to what has been previously believed.
• The sequence reads from bisulfite-treated DNA allowed us to characterize the DNA methylation patterns along chromosomes that originate from individual ALL cells. According to this analysis the highly variable CpG island methylation that we observe in the ALL cells is a consequence of random methylation of CpG sites. 
